Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
14 05 2021
Historique:
received: 01 10 2020
accepted: 12 04 2021
entrez: 15 5 2021
pubmed: 16 5 2021
medline: 4 6 2021
Statut: epublish

Résumé

Chemotherapy remains the standard of care for most cancers worldwide, however development of chemoresistance due to the presence of the drug-effluxing ATP binding cassette (ABC) transporters remains a significant problem. The development of safe and effective means to overcome chemoresistance is critical for achieving durable remissions in many cancer patients. We have investigated the energetic demands of ABC transporters in the context of the metabolic adaptations of chemoresistant cancer cells. Here we show that ABC transporters use mitochondrial-derived ATP as a source of energy to efflux drugs out of cancer cells. We further demonstrate that the loss of methylation-controlled J protein (MCJ) (also named DnaJC15), an endogenous negative regulator of mitochondrial respiration, in chemoresistant cancer cells boosts their ability to produce ATP from mitochondria and fuel ABC transporters. We have developed MCJ mimetics that can attenuate mitochondrial respiration and safely overcome chemoresistance in vitro and in vivo. Administration of MCJ mimetics in combination with standard chemotherapeutic drugs could therefore become an alternative strategy for treatment of multiple cancers.

Identifiants

pubmed: 33990571
doi: 10.1038/s41467-021-23071-6
pii: 10.1038/s41467-021-23071-6
pmc: PMC8121950
doi:

Substances chimiques

ATP-Binding Cassette Transporters 0
Antineoplastic Agents 0
DNAJC15 protein, human 0
HSP40 Heat-Shock Proteins 0
Doxorubicin 80168379AG
Adenosine Triphosphate 8L70Q75FXE

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2804

Subventions

Organisme : NCI NIH HHS
ID : R21 CA223389
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK116073
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI055402
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA127099
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103496
Pays : United States
Organisme : NINDS NIH HHS
ID : P30 NS048154
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI110016
Pays : United States

Références

Gottesman, M. M., Lavi, O., Hall, M. D. & Gillet, J. P. Toward a better understanding of the complexity of cancer drug resistance. Annu. Rev. Pharm. Toxicol. 56, 85–102 (2016).
doi: 10.1146/annurev-pharmtox-010715-103111
Kathawala, R. J., Gupta, P., Ashby, C. R. Jr & Chen, Z. S. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist. Updat. 18, 1–17 (2015).
pubmed: 25554624 doi: 10.1016/j.drup.2014.11.002
Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Disco. 5, 219–234 (2006).
doi: 10.1038/nrd1984
Dean, M., Rzhetsky, A. & Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156–1166 (2001).
pubmed: 11435397 doi: 10.1101/gr.184901
Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452–464 (2018).
pubmed: 29643473 pmcid: 6622180 doi: 10.1038/s41568-018-0005-8
Roninson, I. B. et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl Acad. Sci. USA 83, 4538–4542 (1986).
pubmed: 3459187 doi: 10.1073/pnas.83.12.4538 pmcid: 323769
Ueda, K. et al. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 262, 505–508 (1987).
pubmed: 3027054 doi: 10.1016/S0021-9258(19)75806-2
Cole, S. P. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650–1654 (1992).
pubmed: 1360704 doi: 10.1126/science.1360704
Doyle, L. A. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95, 15665–15670 (1998).
pubmed: 9861027 doi: 10.1073/pnas.95.26.15665 pmcid: 28101
Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V. & Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337–5339 (1998).
pubmed: 9850061
Miyake, K. et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8–13 (1999).
pubmed: 9892175
Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E. & Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468–7485 (2003).
pubmed: 14576852 doi: 10.1038/sj.onc.1206948
Poolman, B. et al. Functional analysis of detergent-solubilized and membrane-reconstituted ATP-binding cassette transporters. Methods Enzymol. 400, 429–459 (2005).
pubmed: 16399364 doi: 10.1016/S0076-6879(05)00025-X
Patzlaff, J. S., van der Heide, T. & Poolman, B. The ATP/substrate stoichiometry of the ATP-binding cassette (ABC) transporter OpuA. J. Biol. Chem. 278, 29546–29551 (2003).
pubmed: 12766159 doi: 10.1074/jbc.M304796200
Pearce, E. L., Poffenberger, M. C., Chang, C. H. & Jones, R. G. Fueling immunity: insights into metabolism and lymphocyte function. Science 342, 1242454 (2013).
pubmed: 24115444 pmcid: 4486656 doi: 10.1126/science.1242454
Liberti, M. V. & Locasale, J. W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem. Sci. 41, 211–218 (2016).
pubmed: 26778478 pmcid: 4783224 doi: 10.1016/j.tibs.2015.12.001
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
doi: 10.1126/science.1160809
Warburg, O. On respiratory impairment in cancer cells. Science 124, 269–270 (1956).
pubmed: 13351639 doi: 10.1126/science.124.3215.269
Wallace, D. C. Mitochondria and cancer. Nat. Rev. Cancer 12, 685–698 (2012).
pubmed: 23001348 pmcid: 4371788 doi: 10.1038/nrc3365
Zong, W. X., Rabinowitz, J. D. & White, E. Mitochondria and Cancer. Mol. Cell 61, 667–676 (2016).
pubmed: 26942671 pmcid: 4779192 doi: 10.1016/j.molcel.2016.02.011
Cierlitza, M. et al. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Exp. Dermatol. 24, 155–157 (2015).
pubmed: 25453510 pmcid: 4335723 doi: 10.1111/exd.12613
Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23, 811–825 (2013).
pubmed: 23764003 doi: 10.1016/j.ccr.2013.05.003
Abdullah, L. N. & Chow, E. K. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2, 3 (2013).
pubmed: 23369605 pmcid: 3565873 doi: 10.1186/2001-1326-2-3
Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036–1046 (2018).
pubmed: 29892070 doi: 10.1038/s41591-018-0052-4
Champagne, D. P. et al. Fine-tuning of CD8(+) T cell mitochondrial metabolism by the respiratory chain repressor MCJ dictates protection to influenza virus. Immunity 44, 1299–1311 (2016).
pubmed: 27234056 pmcid: 4917451 doi: 10.1016/j.immuni.2016.02.018
Barbier-Torres, L. et al. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. Nat. Commun. 8, 2068 (2017).
pubmed: 29233977 pmcid: 5727217 doi: 10.1038/s41467-017-01970-x
Hatle, K. et al. MCJ/DnaJC15, an endogenous mitochondrial repressor of the respiratory chain that controls metabolic alterations. Mol. Cell Biol. 33, 2302–2314 (2013).
pubmed: 23530063 pmcid: 3648061 doi: 10.1128/MCB.00189-13
Barbier-Torres, L. et al. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. Nat. Commun. 11, 3360 (2020).
pubmed: 32620763 pmcid: 7334216 doi: 10.1038/s41467-020-16991-2
Fernandez-Cabezudo, M. J. et al. Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer. JCI insight 1, https://doi.org/10.1172/jci.insight.86873 (2016).
Strathdee, G. et al. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol. Oncol. 97, 898–903 (2005).
pubmed: 15894365 doi: 10.1016/j.ygyno.2005.03.023
Nemkov, T., Reisz, J. A., Gehrke, S., Hansen, K. C. & D’Alessandro, A. High-throughput metabolomics: isocratic and gradient mass spectrometry-based methods. Methods Mol. Biol. 1978, 13–26 (2019).
pubmed: 31119654 doi: 10.1007/978-1-4939-9236-2_2
Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem J. 417, 1–13 (2009).
pubmed: 19061483 doi: 10.1042/BJ20081386
Fairchild, C. R. et al. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47, 5141–5148 (1987).
pubmed: 2441861
Linton, K. J. & Higgins, C. F. Structure and function of ABC transporters: the ATP switch provides flexible control. Pflug. Arch. 453, 555–567 (2007).
doi: 10.1007/s00424-006-0126-x
Westermann, B. The mitochondria-plasma membrane contact site. Curr. Opin. Cell Biol. 35, 1–6 (2015).
pubmed: 25801776 doi: 10.1016/j.ceb.2015.03.001
Cunniff, B., McKenzie, A. J., Heintz, N. H. & Howe, A. K. AMPK activity regulates trafficking of mitochondria to the leading edge during cell migration and matrix invasion. Mol. Biol. Cell 27, 2662–2674 (2016).
pubmed: 27385336 pmcid: 5007087 doi: 10.1091/mbc.e16-05-0286
Rao, A. S. et al. A turn-on two-photon fluorescent probe for ATP and ADP. Chem. Commun. (Camb.) 48, 3206–3208 (2012).
doi: 10.1039/c2cc17629g
Lobas, M. A. et al. A genetically encoded single-wavelength sensor for imaging cytosolic and cell surface ATP. Nat. Commun. 10, 711 (2019).
pubmed: 30755613 pmcid: 6372613 doi: 10.1038/s41467-019-08441-5
Alessandrini, F., Pezze, L., Menendez, D., Resnick, M. A. & Ciribilli, Y. ETV7-Mediated DNAJC15 repression leads to doxorubicin resistance in breast cancer cells. Neoplasia 20, 857–870 (2018).
pubmed: 30025229 pmcid: 6077117 doi: 10.1016/j.neo.2018.06.008
Hatle, K. M. et al. Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression. Mol. Cell Biol. 27, 2952–2966 (2007).
pubmed: 17283040 pmcid: 1899938 doi: 10.1128/MCB.01804-06
Nagahara, H. et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4, 1449–1452 (1998).
pubmed: 9846587 doi: 10.1038/4042
Schwarze, S. R., Ho, A., Vocero-Akbani, A. & Dowdy, S. F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569–1572 (1999).
pubmed: 10477521 doi: 10.1126/science.285.5433.1569
Addya, S. et al. Targeting of NH
pubmed: 9348277 pmcid: 2141697 doi: 10.1083/jcb.139.3.589
Horton, K. L., Stewart, K. M., Fonseca, S. B., Guo, Q. & Kelley, S. O. Mitochondria-penetrating peptides. Chem. Biol. 15, 375–382 (2008).
pubmed: 18420144 doi: 10.1016/j.chembiol.2008.03.015
Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).
pubmed: 25860605 pmcid: 5905674 doi: 10.1016/j.cell.2015.03.030
Chen, Z. et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 370, 153–164 (2016).
pubmed: 26499806 doi: 10.1016/j.canlet.2015.10.010
Tamaki, A., Ierano, C., Szakacs, G., Robey, R. W. & Bates, S. E. The controversial role of ABC transporters in clinical oncology. Essays Biochem. 50, 209–232 (2011).
pubmed: 21967059 pmcid: 6944313 doi: 10.1042/bse0500209
Amiri-Kordestani, L., Basseville, A., Kurdziel, K., Fojo, A. T. & Bates, S. E. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist. Updat. 15, 50–61 (2012).
pubmed: 22464282 pmcid: 3680361 doi: 10.1016/j.drup.2012.02.002
Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325–337 (2011).
pubmed: 21508971 doi: 10.1038/nrc3038
Shridhar, V. et al. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 61, 4258–4265 (2001).
pubmed: 11358853
Li, W. et al. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist. Updat. 27, 14–29 (2016).
pubmed: 27449595 doi: 10.1016/j.drup.2016.05.001
Coley, H. M. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol. Biol. 596, 341–358 (2010).
pubmed: 19949931 doi: 10.1007/978-1-60761-416-6_15
Kohler, S. & Stein, W. D. Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles. Biotechnol. Bioeng. 81, 507–517 (2003).
pubmed: 12514799 doi: 10.1002/bit.10488
Batist, G. et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J. Biol. Chem. 261, 15544–15549 (1986).
pubmed: 3782078 doi: 10.1016/S0021-9258(18)66748-1
Harker, W. G., MacKintosh, F. R. & Sikic, B. I. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res. 43, 4943–4950 (1983).
pubmed: 6883344
Huff, L. M., Lee, J. S., Robey, R. W. & Fojo, T. Characterization of gene rearrangements leading to activation of MDR-1. J. Biol. Chem. 281, 36501–36509 (2006).
pubmed: 16956878 doi: 10.1074/jbc.M602998200
Robey, R. W. et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89, 1971–1978 (2003).
pubmed: 14612912 pmcid: 2394461 doi: 10.1038/sj.bjc.6601370
Robey, R. W. et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem. Pharm. 75, 1302–1312 (2008).
pubmed: 18234154 doi: 10.1016/j.bcp.2007.12.001
Zhan, Z. et al. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother. Pharm. 40, 245–250 (1997).
doi: 10.1007/s002800050654
Divakaruni, A. S., Rogers, G. W. & Murphy, A. N. Measuring mitochondrial function in permeabilized cells using the seahorse XF analyzer or a clark-type oxygen electrode. Curr. Protoc. Toxicol. 60, 25.2.1–25.2.16 (2014).
doi: 10.1002/0471140856.tx2502s60
D’Alessandro, A. et al. Routine storage of red blood cell (RBC) units in additive solution-3: a comprehensive investigation of the RBC metabolome. Transfusion 55, 1155–1168 (2015).
pubmed: 25556331 doi: 10.1111/trf.12975
Nemkov, T., Hansen, K. C. & D’Alessandro, A. A three-minute method for high-throughput quantitative metabolomics and quantitative tracing experiments of central carbon and nitrogen pathways. Rapid Commun. Mass Spectrom. 31, 663–673 (2017).
pubmed: 28195377 pmcid: 5364945 doi: 10.1002/rcm.7834
D’Alessandro, A. et al. Citrate metabolism in red blood cells stored in additive solution-3. Transfusion 57, 325–336 (2017).
pubmed: 27813142 doi: 10.1111/trf.13892
Jones, C. L. et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell 34, 724–740.e724 (2018).
pubmed: 30423294 pmcid: 6280965 doi: 10.1016/j.ccell.2018.10.005
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
pubmed: 22930834 pmcid: 5554542 doi: 10.1038/nmeth.2089
Rueden, C. T. et al. ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinforma. 18, 529 (2017).
doi: 10.1186/s12859-017-1934-z
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
doi: 10.1038/nmeth.2019 pubmed: 22743772

Auteurs

Emily L Giddings (EL)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Devin P Champagne (DP)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Meng-Han Wu (MH)

Department of Immunology and Microbiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.

Joshua M Laffin (JM)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Tina M Thornton (TM)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Felipe Valenca-Pereira (F)

Department of Immunology and Microbiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.

Rachel Culp-Hill (R)

Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.

Karen A Fortner (KA)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Natalia Romero (N)

Cell Analysis Division, Agilent Technologies, Lexington, MA, USA.

James East (J)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Radiology, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Phoebe Cao (P)

Department of Immunology and Microbiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.

Hugo Arias-Pulido (H)

Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.

Karatatiwant S Sidhu (KS)

Department of Chemistry, University of Vermont, Burlington, VT, USA.

Brian Silverstrim (B)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Yoonseok Kam (Y)

Cell Analysis Division, Agilent Technologies, Lexington, MA, USA.

Shana Kelley (S)

Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.

Mark Pereira (M)

Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.

Susan E Bates (SE)

Division of Hematology/Oncology, Columbia University Medical Center, New York City, NY, USA.

Janice Y Bunn (JY)

Department of Medical Biostatistics, University of Vermont, Burlington, VT, USA.

Steven N Fiering (SN)

Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.

Dwight E Matthews (DE)

Department of Chemistry, University of Vermont, Burlington, VT, USA.

Robert W Robey (RW)

Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Domink Stich (D)

Advanced Light Microscopy Core, Neurotechnology Center, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.

Angelo D'Alessandro (A)

Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. Angelo.Dalessandro@cuanschutz.edu.

Mercedes Rincon (M)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA. Mercedes.Rincon@cuanschutz.edu.
Department of Immunology and Microbiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. Mercedes.Rincon@cuanschutz.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH